






### HEALTH CARE LAW

IN THE NEWS

July 2012



# 340B Drug Pricing Program Experiencing Unprecedented Compliance Scrutiny

A Polsinelli Shughart Update

articipants in the 340B Drug Program (340B Pricing Program) should be aware that over the last several months, the 340B Program has witnessed an unprecedented focus on oversight, integrity and enforcement. Although the 340B Program was enacted as part of the Veterans Health Care Act of 1992, its expansion of the types of providers that were made eligible in Patient Protection and Affordable Care Act of 2010 (ACA) has ignited recent scrutiny by Congress, federal government agencies and the pharmaceutical industry to verify participants' compliance with the 340B Program.

The 340B Program requires drug companies to give discounts on outpatient drugs to certain health care providers (Covered Entities) who serve patients who have little or no insurance coverage. From 2001 to 2011, the number of Covered Entities almost doubled, reaching slightly more than 16,500, and, under ACA, additional types of providers were made eligible further expanding the pool of providers to receive the drug discounts. Providers eligible to be Covered Entities under the 340B Program include federal grantees, federallyqualified health center look-alikes and qualified hospitals.

Chicago | Dallas | Denver | Edwardsville | Jefferson City | Kansas City | Los Angeles | New York Overland Park | Phoenix | St. Joseph | St. Louis | Springfield | Topeka | Washington DC | Wilmington

polsinelli.com

### Catalysts of the Compliance Environment

Recently, two government reports have catalyzed increases in enforcement and oversight of the 340B Program, which is administered by Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA). Under the 340B Program guidelines, Covered Entities may not accept a discount for a drug that would also generate a Medicaid rebate (duplicate discount) and may not sell discounted drugs to persons who are not patients of the hospital (drug diversion).

In June of 2011, the Department of Health and Human Services, the Office of Inspector General, released a report questioning the effectiveness of federal and state on Medicaid-related billing from 340B guidance Additionally, the Government Accountability participants. Office released a report in September of 2011 pointing out the government's overreliance on participating providers self-policing of their actions. The GAO report recommended greater government oversiaht and enforcement.

In addition to these reports, in March and May of 2012, members of Congress requested information from various 340B Program stakeholders including two drug industry groups, a hospital group, the nonprofit contractor that serves as the 340B program's prime vendor and two health care providers. The congressional inquiries request information pertaining to each stakeholder's role in the 340B program, following the 2011 reports of insufficient oversight and calling for transparency in the 340B Program.

### HRSA Program Integrity Response

Stemming from provisions in the ACA, HRSA has begun to conduct audits to address compliance issues concerning Covered Entity drug diversion and duplicative discounting practices. In a February 2012 letter to 340B Program Participants, HRSA highlighted the importance of strengthening oversight of both participating Covered Entities and manufacturers to ensure compliance and outlined several key components of HRSA's program integrity efforts. In a March 2012 policy release, HRSA clarified its intent and procedure to audit Covered Entities. HRSA stated the purpose of the audits is to help HRSA and participating Covered Entities identify and mitigate program risk as well as identify best practices regarding 340B Program compliance. HRSA explains it will conduct both random and targeted Covered Entity audits.

According to the release, HRSA's random audits of higher risk programs are to be conducted first, and then HRSA's focus will shift lesser risk programs. HRSA looks at various criteria to determine whether a Covered Entity's program is high risk, including volume of purchases, complexity of program administration, and use of contract pharmacies. Hospitals generally have higher risk programs because they involve most of these components and serve both 340B and non-340B patients. Targeted audits can be triggered by allegations of violations of 340B requirements from whistleblowers, manufacturers, hospital self-reporting, or other source and include a more thorough investigation of policies and procedures, review of auditable records, and system compliance to prevent diversion and duplicate discounts. HRSA has stated that non-compliance issues uncovered in its audit may be used to refer matters to the Office of Inspector General or Department of Justice.



On June 19, 2012, the OPA published additional guidance regarding the scope and process of HRSA's Covered Entity audits. The document is meant to increase Covered Entity and manufacturer understanding of HRSA's audit objectives by providing a short summary of HRSA's pre, onsite and post audit procedures. Pre-audit protocols include general information requests from HRSA. Onsite audit procedures are composed of various investigations, including a review of contract pharmacy compliance and a sample testing of 340B drug transaction records. Post audit, HRSA forwards its findings to the OPA, and the OPA works directly with the Covered Entity to address concerns, remedies and any necessary corrective action. Finalized reports summarizing the audit findings and the Covered Entity's response will be posted on the OPA's website.

# On the Horizon: ACA's Addition of Section 340B(d) Improvements in Program Integrity

Under the ACA, HRSA was granted authority to impose sanctions in the form of civil monetary penalties against Covered Entities. In addition to the penalties to which Covered Entities are already subject under Section 340B(a)(5)(D), HRSA will have the authority to require Covered Entities to pay monetary penalties to manufacturers in the form of compounded interest for knowing and intentional violations of diversion and/or removing and disqualifying the covered entity from the 340B Program for a designated period of time as penalty when diversion violations are found to be systematic and egregious. Notably, however, HRSA stated that due to funding limitations these new authorities and responsibilities have *not* yet been fully implemented.

### What Covered Entities Should Do Now


Participating Covered Entities should stay abreast of HRSA's increased program enforcement and be aware of the increasing oversight. Covered Entities should make sure to maintain auditable records available in case of a HRSA or manufacturer audit. Policies and preventing diversion and procedures duplicate discounting and describing implemented compliance safeguards should be reviewed and fine-tuned as required. Verification of Covered Entity eligibility and a review of contract pharmacy compliance is also encouraged. By effectively monitoring its 340B program while ensuring compliance with HRSA guidelines, a Covered Entity can take a proactive role in managing its 340B program in this heightened compliance environment.



# For More Information

To learn more about any of these issues or the 340B Drug Pricing Program generally, please contact:

- Mary Beth Blake | 816.360.4284 | mblake@polsinelli.com
- Alan Parver | 202.626.8306 | aparver@polsinelli.com
- Cynthia Berry | 202.626.8333 | ceberry@polsinelli.com
- Lauren Groebe | 816.572.4588 | Igroebe@polsinelli.com



### July 2012

Matthew J. Murer Practice Area Chair *Chicago* 312.873.3603 mmurer@polsinelli.com

Colleen M. Faddick Practice Area Vice-Chair Denver 303.583.8201 cfaddick@polsinelli.com

Bruce A. Johnson Practice Area Vice-Chair Denver 303.583.8203 brucejohnson@polsinelli.com

Alan K. Parver Practice Area Vice-Chair Washington, D.C. 202.626.8306 aparver@polsinelli.com

Janice A. Anderson Chicago 312.873.3623 janderson@polsinelli.com

Douglas K. Anning Kansas City 816.360.4188 danning@polsinelli.com

Jane E. Arnold St. Louis 314.622.6687 jarnold@polsinelli.com

Jack M. Beal Kansas City 816.360.4216 jbeal@polsinelli.com

Cynthia E. Berry Washington, D.C. 202.626.8333 ceberry@polsinelli.com

Mary Beth Blake Kansas City 816.360.4284 mblake@polsinelli.com Gerald W. Brenneman Kansas City 816.360.4221 gbrenneman@polsinelli.com

Jared O. Brooner St. Joseph 816.364.2117 jbrooner@polsinelli.com

Lawrence C. Conn Los Angeles 310.203.5336 Iconn@polsinelli.com

Anne M. Cooper Chicago 312.873.3606 acooper@polsinelli.com

Lauren P. DeSantis-Then Washington, D.C. 202.626.8323 Idesantis@polsinelli.com

S. Jay Dobbs St. Louis 314.552.6847 jdobbs@polsinelli.com

Thomas M. Donohoe Denver 303.583.8257 tdonohoe@polsinelli.com

Cavan K. Doyle Chicago 312.873.3685 cdoyle@polsinelli.com

Meredith A. Duncan Chicago 312.873.3602 mduncan@polsinelli.com

Erin Fleming Dunlap St. Louis 314.622.6661 edunlap@polsinelli.com Fredric J. Entin Chicago 312.873.3601 fentin@polsinelli.com

Jennifer L. Evans Denver 303.583.8211 jevans@polsinelli.com

T. Jeffrey Fitzgerald Denver 303.583.8205 jfitzgerald@polsinelli.com

Kara M. Friedman Chicago 312.873.3639 kfriedman@polsinelli.com

> Rebecca L. Frigy St. Louis 314.889.7013 rfrigy@polsinelli.com

Asher D. Funk Chicago 312.873.3635 afunk@polsinelli.com

Randy S. Gerber St. Louis 314.889.7038 rgerber@polsinelli.com

Mark H. Goran St. Louis 314.622.6686 mgoran@polsinelli.com

Linas J. Grikis Chicago 312.873.2946 Igrikis@polsinelli.com

Lauren Z. Groebe Kansas City 816.572.4588 Igroebe@polsinelli.com

#### HEALTH CARE | ATTORNEYS

Brett B. Heger St. Louis 314.622.6664 bheger@polsinelli.com

Jonathan K. Henderson Dallas 214.397.0016 jhenderson@polsinelli.com

Margaret H. Hillman St. Louis 314.622.6663 Imhillman@polsinelli.com

Jay M. Howard Kansas City 816.360.4202 jhoward@polsinelli.com

> Sara V. lams Denver 303.583.8207 siams@polsinelli.com

George Jackson, III Chicago 312.873.3657 gjackson@polsinelli.com

Joan B. Killgore St. Louis 314.889.7008 jkillgore@polsinelli.com

Anne. L. Kleindienst Phoenix 602.650.2392 akleindienst@polsinelli.com



### July 2012

#### Chad K. Knight Dallas 214.397.0017 cknight@polsinelli.com

Dana M. Lach Chicago 312.873.2993 dlach@polsinelli.com

Jason T. Lundy Chicago 312.873.3604 jlundy@polsinelli.com

Ryan M. McAteer Los Angeles 30.203.5368 rmcateer@polsinelli.com

Jane K. McCahill Chicago 312.873.3607 jmccahill@polsinelli.com

Ann C. McCullough Denver 303.583.8202 amccullough@polsinelli.com

Aileen T. Murphy Denver 303.583.8210 amurphy@polsinelli.com Gerald A. Niederman Denver 303.583.8204 gniederman@polsinelli.com

Edward F. Novak Phoenix 602.650.2020 enovak@polsinelli.com

Thomas P. O'Donnell Kansas City 816.360.4173 todonnell@polsinelli.com

Aaron E. Perry Chicago 312.873.3683 aperry@polsinelli.com

Mitchell D. Raup Washington D.C. 202.626.8352 mraup@polsinelli.com

Daniel S. Reinberg Chicago 312.873.3636 dreinberg@polsinelli.com

Donna J. Ruzicka St. Louis 314.622.6660 druzicka@polsinelli.com Charles P. Sheets Chicago 312.873.3605 csheets@polsinelli.com

Kathryn M. Stalmack Chicago 312.873.3608 kstalmack@polsinelli.com

Leah Mendelsohn Stone Washington, D.C. 202.626.8329 Istone@polsinelli.com

Chad C. Stout Kansas City 816.572.4479 cstout@polsinelli.com

Steven K. Stranne Washington, D.C. 202.626.8313 sstranne@polsinelli.com

William E. Swart Dallas 214.397.0015 bswart@polsinelli.com

Tennille A. Syrstad Denver 303.583.8263 tsyrstad@polsinelli.com

#### Emily C. Tremmel Chicago 312.873.3661 etremmel@polsinelli.com

Andrew B. Turk Phoenix 602.650.2097 abturk@polsinelli.com

Joseph T. Van Leer Chicago 312.873.3665 jvanleer@polsinelli.com

Joshua M. Weaver Dallas 214.661.5514 jweaver@polsinelli.com


> Emily Wey Denver 303.583.8255 ewey@polsinelli.com

Mark R. Woodbury St. Joseph 816.364.2117 mwoodbury@polsinelli.com

> Janet E. Zeigler Chicago 312.873.3679 jzeigler@polsinelli.com

## Additional Health Care Professionals

Julius W. Hobson, Jr. Washington, D.C. 202.626.8354 jhobson@polsinelli.com Beverly A. Pheto Washington, D.C. 202.626.8352 bpheto@polsinelli.com Harry Sporidis Washington, D.C. 202.626.8349 hsporidis@polsinelli.com



### HEALTH CARE | ATTORNEYS

# About Polsinelli Shughart's

# Health Care Group

The Health Care group has vast national resources and strong Washington, D.C. connections. With highly trained, regulatoryexperienced attorneys practicing health care law in offices across the country, we are familiar with the full range of hospital -physician lifecycle and business issues confronting hospitals today. A mix of talented, bright, young attorneys and seasoned attorneys, well known in the health care industry, make up our robust health care team.

Polsinelli Shughart is the 10th largest health care law firm in the nation, according to the 2010 rankings from Modern Healthcare magazine. The publication annually ranks law firms based on their total membership in the American Health Lawyers Association. With one of the fastest-growing health care practices in the nation, Polsinelli Shughart has the depth and experience to provide a broad spectrum of health care law services.

# About Polsinelli Shughart

With more than 600 attorneys, Polsinelli Shughart (<u>www.polsinelli.com</u>) is a national law firm and recognized leader in the areas of health care, financial services, real estate, life sciences, energy and business litigation. Serving corporate, institutional and individual clients, the firm builds enduring relationships by creating value through our legal services - with passion, ingenuity and a sense of urgency. The firm has offices in Chicago; Dallas; Denver; Kansas City; Los Angeles; New York; Phoenix; St. Louis; Washington, D.C.; and Wilmington, DE.

In California, Polsinelli Shughart LLP.

## About

# This Publication

If you know of anyone who you believe would like to receive our e-mail updates, or if you would like to be removed from our edistribution list, please contact us via e-mail at Interaction@polsinelli.com.

Polsinelli Shughart provides this material for informational purposes only. The material provided herein is general and is not intended to be legal advice. Nothing herein should be relied upon or used without consulting a lawyer to consider your specific circumstances, possible changes to applicable laws, rules and regulations and other legal issues. Receipt of this material does not establish an attorney-client relationship.

Polsinelli Shughart is very proud of the results we obtain for our clients, but you should know that past results do not guarantee future results; that every case is different and must be judged on its own merits; and that the choice of a lawyer is an important decision and should not be based solely upon advertisements.

Polsinelli Shughart PC. In California, Polsinelli Shughart LLP.

 $\label{eq:polsinelli} \textit{Shughart} \circledast \textit{ is a registered trademark of Polsinelli Shughart PC}.$ 

